How to buy Intec Pharma stock - 02 March

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Intec Pharma stock

Own Intec Pharma stock in just a few minutes.

Fact checked

Intec Pharma Ltd is a biotechnology business based in the US. Intec Pharma shares (NTEC) are listed on the NASDAQ and all prices are listed in US Dollars. Intec Pharma employs 38 staff and has a market cap (total outstanding shares value) of USD$19.3 million.

How to buy shares in Intec Pharma

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Intec Pharma. Find the stock by name or ticker symbol: NTEC. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Intec Pharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Intec Pharma, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Intec Pharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Intec Pharma share price

Use our graph to track the performance of NTEC stocks over time.

Intec Pharma shares at a glance

Information last updated 2021-02-23.
52-week rangeUSD$2.2 - USD$11.2
50-day moving average USD$4.8612
200-day moving average USD$4.711
Wall St. target priceUSD$9
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.276

Buy Intec Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Intec Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Intec Pharma financials

Gross profit TTM USD$0
Return on assets TTM -28.25%
Return on equity TTM -96.24%
Profit margin 0%
Book value $4.579
Market capitalisation USD$19.3 million

TTM: trailing 12 months

Shorting Intec Pharma shares

There are currently 511,124 Intec Pharma shares held short by investors – that's known as Intec Pharma's "short interest". This figure is 4.2% up from 490,548 last month.

There are a few different ways that this level of interest in shorting Intec Pharma shares can be evaluated.

Intec Pharma's "short interest ratio" (SIR)

Intec Pharma's "short interest ratio" (SIR) is the quantity of Intec Pharma shares currently shorted divided by the average quantity of Intec Pharma shares traded daily (recently around 719892.95774648). Intec Pharma's SIR currently stands at 0.71. In other words for every 100,000 Intec Pharma shares traded daily on the market, roughly 710 shares are currently held short.

However Intec Pharma's short interest can also be evaluated against the total number of Intec Pharma shares, or, against the total number of tradable Intec Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intec Pharma's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Intec Pharma shares in existence, roughly 130 shares are currently held short) or 0.1302% of the tradable shares (for every 100,000 tradable Intec Pharma shares, roughly 130 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Intec Pharma.

Find out more about how you can short Intec Pharma stock.

Intec Pharma share dividends

We're not expecting Intec Pharma to pay a dividend over the next 12 months.

Have Intec Pharma's shares ever split?

Intec Pharma's shares were split on a 1:20 basis on 30 October 2020. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Intec Pharma shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Intec Pharma shares which in turn could have impacted Intec Pharma's share price.

Intec Pharma share price volatility

Over the last 12 months, Intec Pharma's shares have ranged in value from as little as $2.2 up to $11.2. A popular way to gauge a stock's volatility is its "beta".

NTEC.US volatility(beta: 1.21)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intec Pharma's is 1.2065. This would suggest that Intec Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Intec Pharma overview

Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program; and a feasibility agreement with GW Research Limited to explore an undisclosed research program using the Accordion Pill platform. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was founded in 2000 and is based in Jerusalem, Israel.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site